Management of Lithium-Induced Tremor
For lithium-induced tremor, pharmacotherapy with beta-blockers (propranolol 30-40 mg daily in divided doses) is indicated only when tremor is disabling, after first optimizing lithium dosing and eliminating contributing factors. 1, 2
Initial Assessment and Differential Diagnosis
When lithium tremor develops, conduct the following evaluation:
- Obtain serum lithium level to rule out toxicity (severe tremor may indicate lithium toxicity) 1, 3
- Check metabolic parameters including thyroid function, renal function (BUN, creatinine), and serum calcium 4
- Review medication list for drugs that may exacerbate tremor or interact with lithium 3
- Characterize the tremor: lithium tremor is classified as a postural tremor, specifically an exaggerated physiologic tremor affecting distal extremities with irregular, nonrhythmic characteristics 1, 2
The differential diagnosis includes benign essential tremor, Parkinson's disease, metabolic abnormalities, and lithium toxicity 1.
Stepwise Management Algorithm
Step 1: Non-Pharmacological Interventions
- Adjust lithium dosing schedule: Consider changing the lithium preparation or timing of doses 3
- Reduce or eliminate other medications that may contribute to tremor 3
- Monitor over time: Lithium tremor often decreases spontaneously with continued lithium therapy 3
Step 2: Pharmacological Treatment (Only for Disabling Tremor)
Beta-blockers are first-line pharmacotherapy:
- Propranolol 30-40 mg daily in divided doses (individually adjusted) remains effective with long-term administration without requiring dose escalation 2
- Nadolol is an alternative for patients with compromised liver function, as it has no hepatic biotransformation (unlike propranolol which is metabolized in the liver) 5
Alternative agents with limited evidence:
- Primidone has been proposed as an option 3
- Vitamin B6 (900-1200 mg/day) showed impressive improvement in a small open-label case series of 5 patients, with 4 achieving complete tremor resolution without side effects, though double-blind controlled trials are needed 6
Important Clinical Considerations
- Do not discontinue lithium prematurely: Maintenance therapy is often needed long-term, with withdrawal associated with increased relapse risk, especially within 6 months of discontinuation 4
- Balance risks versus benefits: Weigh the impact of tremor on quality of life against the risk of mood episode recurrence if lithium is discontinued 4
- Regular monitoring is essential: Follow-up should include symptom assessment, side effect monitoring (including tremor evaluation), and laboratory monitoring every 3-6 months 4
- Standardized assessment: Use validated tremor scales (such as the Simpson-Angus Scale tremor subscale) rather than subjective clinical impression alone 6
Common Pitfalls to Avoid
- Overlooking tremor in clinical practice: Tremor occurs frequently (reported incidence ranges from 4-65% depending on definition) but is easily missed 1, 3
- Treating non-disabling tremor pharmacologically: Reserve beta-blockers for disabling tremor only 1
- Using propranolol in liver disease: Select nadolol instead for patients with hepatic compromise 5
- Failing to check lithium levels: Always rule out toxicity before treating as a simple side effect 1, 3